In fact, about 40% of people (based on female trials) experienced nausea after a 1.75 mg dose, compared to only ~1% on placebo
FDA approval means the agency verified not only that tirzepatide works, but that this specific formulation, made this specific way, in these specific doses, produces consistent and acceptable results
At Genesis Lifestyle Medicine, were here to support your health journey wherever life takes you
"Fatty liver disease is estimated to affect up to one in five people in Sweden, many of whom have type 2 diabetes, and about one in twenty develop severe liver disease," study first author Axel Wester, assistant professor at the Department of Medicine, Huddinge, Karolinska Institutet, said in a press release